354 related articles for article (PubMed ID: 30064039)
21. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
Shaffer BC; Le Luduec JB; Forlenza C; Jakubowski AA; Perales MA; Young JW; Hsu KC
Biol Blood Marrow Transplant; 2016 Apr; 22(4):705-709. PubMed ID: 26772158
[TBL] [Abstract][Full Text] [Related]
22. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
23. Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse.
Kharfan-Dabaja MA; Labopin M; Polge E; Nishihori T; Bazarbachi A; Finke J; Stadler M; Ehninger G; Lioure B; Schaap N; Afanasyev B; Yeshurun M; Isaksson C; Maertens J; Chalandon Y; Schmid C; Nagler A; Mohty M
JAMA Oncol; 2018 Sep; 4(9):1245-1253. PubMed ID: 30003233
[TBL] [Abstract][Full Text] [Related]
24. Managing post allograft relapse of myeloid neoplasms: azacitidine and donor lymphocyte infusions as salvage therapy.
Claiborne J; Bandyopathyay D; Roberts C; Hawks K; Aziz M; Simmons G; Wiedl C; Chung H; Clark W; McCarty J; Toor A
Leuk Lymphoma; 2019 Nov; 60(11):2733-2743. PubMed ID: 31046498
[TBL] [Abstract][Full Text] [Related]
25. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
26. Time to unrelated donor leukocyte infusion is longer, but incidence of GVHD and overall survival are similar for recipients of unrelated DLI compared to matched sibling DLI.
Kumar AJ; Vassilev P; Loren AW; Luger SM; Reshef R; Gill S; Smith J; Goldstein SC; Hexner E; Stadtmauer EA; Porter D; Frey NV
Am J Hematol; 2016 Jun; 91(4):426-9. PubMed ID: 26820493
[TBL] [Abstract][Full Text] [Related]
27. [Therapeutic efficacies of decitabine application prior to hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia].
Zhou J; Wang J; Liu H; Zheng H; Ma L; Wang P; Yan S; Wu D; Fu C; Qiu H; Tang X; Jin Z; Han Y; Miao M
Zhonghua Yi Xue Za Zhi; 2015 Mar; 95(12):920-4. PubMed ID: 26081055
[TBL] [Abstract][Full Text] [Related]
28. A Multicenter Phase 2 Clinical Trial of 10-Day Decitabine, Dose-Escalated Donor Lymphocyte Infusion, and Ruxolitinib for Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Cell Transplantation.
Rashidi A; Huselton EJ; Stefanski HE; DeFor TE; Shanley R; Choi J; DiPersio JF; Juckett M; Miller JS; Weisdorf DJ; Schroeder MA
Transplant Cell Ther; 2023 May; 29(5):328.e1-328.e6. PubMed ID: 36804933
[TBL] [Abstract][Full Text] [Related]
29. Single-center experience suggests donor lymphocyte infusion may promote long-term survival in children with high-risk acute lymphoblastic leukemia.
Liberio N; Robinson H; Nugent M; Simpson P; Margolis DA; Malarkannan S; Keever-Taylor C; Thakar MS
Pediatr Blood Cancer; 2019 Nov; 66(11):e27950. PubMed ID: 31368194
[TBL] [Abstract][Full Text] [Related]
30. Cladribine- and decitabine-containing conditioning regimen has a low post-transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Tong X; Li M; Jin J; Li Y; Li L; Peng Y; Huang L; Xu B; Meng F; Mao X; Huang L; Huang W; Zhang D
Int J Cancer; 2023 May; 152(10):2123-2133. PubMed ID: 36594582
[TBL] [Abstract][Full Text] [Related]
31. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
32. Sequential treatment combining cladribine-based re-induction, myeloablative allogeneic HSCT, and prophylactic donor lymphocyte infusion: a promising treatment for refractory acute myeloid leukemia.
Xiao H; Li L; Pang Y; Wu Y; Jiang Z; Liu Z; Wu J; Xiao Y; Huang F; Liu Q; Zhang H; Luo Y; Huang H
Ann Hematol; 2018 Dec; 97(12):2479-2490. PubMed ID: 30078144
[TBL] [Abstract][Full Text] [Related]
33. Donor Lymphocyte Infusion Is a Feasible Way to Improve Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Who Relapse after Allogeneic Stem Cell Transplantation.
Minculescu L; Reekie J; Petersen SL; Kornblit BT; Schjoedt I; Andersen NS; Andersen LP; Fischer-Nielsen A; Haastrup EK; Friis LS; Sengelov H
Acta Haematol; 2024; 147(3):325-332. PubMed ID: 37827141
[TBL] [Abstract][Full Text] [Related]
34. Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant.
Lulla PD; Naik S; Vasileiou S; Tzannou I; Watanabe A; Kuvalekar M; Lulla S; Carrum G; Ramos CA; Kamble R; Hill L; Randhawa J; Gottschalk S; Krance R; Wang T; Wu M; Robertson C; Gee AP; Chung B; Grilley B; Brenner MK; Heslop HE; Vera JF; Leen AM
Blood; 2021 May; 137(19):2585-2597. PubMed ID: 33270816
[TBL] [Abstract][Full Text] [Related]
35. Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation.
Ghobadi A; Choi J; Fiala MA; Fletcher T; Liu J; Eissenberg LG; Abboud C; Cashen A; Vij R; Schroeder MA; Pusic I; Stockerl-Goldstein K; Jacoby M; Uy G; DiPersio J; Westervelt P
Leuk Res; 2016 Oct; 49():1-6. PubMed ID: 27505705
[TBL] [Abstract][Full Text] [Related]
36. Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study.
Zhang R; Wang L; Chen P; Gao X; Wang S; Li F; Dou L; Gao C; Li Y; Liu D
Cancer Med; 2021 May; 10(10):3165-3176. PubMed ID: 33932107
[TBL] [Abstract][Full Text] [Related]
37. Preemptive low-dose interleukin-2 or DLI for late-onset minimal residual disease in acute leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Yuan XL; Tan YM; Shi JM; Zhao YM; Yu J; Lai XY; Yang LX; Huang H; Luo Y
Ann Hematol; 2021 Feb; 100(2):517-527. PubMed ID: 33128124
[TBL] [Abstract][Full Text] [Related]
38. [Analysis of Decitabine Therapeutic Effeicacy for Patients with Relapsed MDS/AML and High-Risk AML Patients after HSCT].
Wang QY; Liang ZY; Dong YJ; Yin Y; Wang Q; Liu W; Xu WL; Li Y; Ren HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):248-254. PubMed ID: 32027285
[TBL] [Abstract][Full Text] [Related]
39. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
[TBL] [Abstract][Full Text] [Related]
40. Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial.
Schroeder T; Stelljes M; Christopeit M; Esseling E; Scheid C; Mikesch JH; Rautenberg C; Jäger P; Cadeddu RP; Drusenheimer N; Holtick U; Klein S; Trenschel R; Haas R; Germing U; Kröger N; Kobbe G
Haematologica; 2023 Nov; 108(11):3001-3010. PubMed ID: 37259567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
